www.innocyto.com.cn

InnoCyto Inc.

15375 Barranca Pkwy, Suite I-103
Irvine, CA 92618
Email: info@innocyto.com
Phone: 1-949-418-7543

Anti-Human TAG-72 (Minretumomab Biosimilar)

Catalog Number:	503701, 503702, 503703
Size:	1 mg, 5 mg, 20 mg
Target Name:	TAG-72, TAG72, Tumor-associated glycoprotein 72
Regulatory Status:	RUO

PRODUCT DETAILS

Clone:	Minretumomab
Application:	Flow cytometry, animal model study
Reactivity:	Human
Format:	Liquid
Product Description:	Minretumomab Biosimilar, TAG-72 Monoclonal Antibody
Isotype:	Human IgG1
Clonality:	Recombinant
Immunogen:	Human TAG-72
Species specificity:	Human
Purity:	>95% by reducing SDS-PAGE
Grade:	In vivo
Storage Conditions:	4ºC
Maximal Shelf Life:	12 months
RRID:	AB_3739313
Antibody Type:	Recombinant
Reactivity:	Human

BACKGROUND INFORMATION

Minretumomab is a humanized monoclonal antibody belonging to the immunoglobulin G1 (IgG1) subclass, engineered to specifically recognize and bind to TAG-72 (tumor-associated glycoprotein 72). It consists of two identical heavy chains and two identical light chains joined by disulfide bonds, forming the typical Y-shaped antibody structure. Produced in mammalian expression systems such as Chinese Hamster Ovary (CHO) cells, it undergoes controlled post-translational modifications to ensure proper folding, stability, and glycosylation patterns essential for its biological function.

The variable regions of Minretumomab (the antigen-binding (Fab) fragments) contain complementarity-determining regions (CDRs) responsible for high-affinity recognition of TAG-72, a high-molecular-weight, mucin-like glycoprotein found on the surface of many cancer cells, particularly adenocarcinomas (breast, colon, pancreatic, ovarian, and lung).

The Fc–FcRn (neonatal Fc receptor) interaction provides extended serum half-life and molecular stability through recycling.

This product is supplied subject to the terms and conditions at www.innocyto.com.cn/web/terms.php and may only be used as provided in the stated terms. Products are for Research Use Only.